Value of Whole-body Magnetic Resonance Imaging Using the MET-RADS-P Criteria for Assessing the Response to Intensified Androgen Deprivation Therapy in Metastatic Hormone-naïve and Castration-resistant Prostate Cancer
We evaluated the agreement between routine PSA (prostate-specific antigen) test results and whole-body MRI (magnetic resonance imaging) scans for assessing the response of metastatic prostate cancer to treatment. There was disagreement between the PSA and MRI results, mainly for patients with cancer that was resistant to hormone-based treatment. Combining PSA with whole-body MRI might provide a more accurate picture of the response of advanced prostate cancer to treatment.
Authors
- J. Van Damme (ORCID: https://orcid.org/0000-0003-1670-3758)
- Perrine Triqueneaux
- Vassiliki Pasoglou (ORCID: https://orcid.org/0000-0001-7815-5086)
- Bertrand Tombal (ORCID: https://orcid.org/0000-0002-0093-8408)
- Frederic E. Lecouvet (ORCID: https://orcid.org/0000-0003-3568-3254)
- Anwar R. Padhani (ORCID: https://orcid.org/0000-0002-5830-5777)
- Sandy Van Nieuwenhove (ORCID: https://orcid.org/0000-0003-2309-4284)
- Nicolas Michoux (ORCID: https://orcid.org/0000-0003-0104-0744)
Institutions
- Cliniques Universitaires Saint-Luc (BE)
- Mount Vernon Hospital (GB)
- UCLouvain (BE)
Publication Details
- Journal
- European Urology Oncology
- Published
- 2024-11-06
- DOI
- https://doi.org/10.1016/j.euo.2024.10.009
- Citations
- 4
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.68